South Korea · Delayed Price · Currency is KRW PanGen Biotech Statistics
Total Valuation
PanGen Biotech has a market cap or net worth of KRW 67.98 billion. The enterprise value is 56.28 billion.
| Market Cap | 67.98B |
| Enterprise Value | 56.28B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
PanGen Biotech has 13.51 million shares outstanding. The number of shares has increased by 14.18% in one year.
| Current Share Class | 13.51M |
| Shares Outstanding | 13.51M |
| Shares Change (YoY) | +14.18% |
| Shares Change (QoQ) | +1.12% |
| Owned by Insiders (%) | 4.06% |
| Owned by Institutions (%) | n/a |
| Float | 6.39M |
Valuation Ratios
The trailing PE ratio is 34.67.
| PE Ratio | 34.67 |
| Forward PE | n/a |
| PS Ratio | 4.96 |
| PB Ratio | 2.22 |
| P/TBV Ratio | 2.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.34, with an EV/FCF ratio of -83.64.
| EV / Earnings | 27.25 |
| EV / Sales | 4.11 |
| EV / EBITDA | 20.34 |
| EV / EBIT | 43.71 |
| EV / FCF | -83.64 |
Financial Position
The company has a current ratio of 8.67, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.67 |
| Quick Ratio | 5.80 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.36 |
| Debt / FCF | -1.50 |
| Interest Coverage | 8.48 |
Financial Efficiency
Return on equity (ROE) is 7.33% and return on invested capital (ROIC) is 7.13%.
| Return on Equity (ROE) | 7.33% |
| Return on Assets (ROA) | 2.50% |
| Return on Invested Capital (ROIC) | 7.13% |
| Return on Capital Employed (ROCE) | 4.19% |
| Weighted Average Cost of Capital (WACC) | 3.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.30 |
Taxes
In the past 12 months, PanGen Biotech has paid 2.91 million in taxes.
| Income Tax | 2.91M |
| Effective Tax Rate | 0.14% |
Stock Price Statistics
The stock price has decreased by -20.41% in the last 52 weeks. The beta is -0.10, so PanGen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | -20.41% |
| 50-Day Moving Average | 5,704.90 |
| 200-Day Moving Average | 5,690.35 |
| Relative Strength Index (RSI) | 41.30 |
| Average Volume (20 Days) | 140,659 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PanGen Biotech had revenue of KRW 13.71 billion and earned 2.06 billion in profits. Earnings per share was 145.10.
| Revenue | 13.71B |
| Gross Profit | 4.44B |
| Operating Income | 1.29B |
| Pretax Income | 2.07B |
| Net Income | 2.06B |
| EBITDA | 2.77B |
| EBIT | 1.29B |
| Earnings Per Share (EPS) | 145.10 |
Balance Sheet
The company has 12.71 billion in cash and 1.01 billion in debt, with a net cash position of 11.70 billion or 865.52 per share.
| Cash & Cash Equivalents | 12.71B |
| Total Debt | 1.01B |
| Net Cash | 11.70B |
| Net Cash Per Share | 865.52 |
| Equity (Book Value) | 30.67B |
| Book Value Per Share | 2,247.70 |
| Working Capital | 21.06B |
Cash Flow
In the last 12 months, operating cash flow was -275.57 million and capital expenditures -397.37 million, giving a free cash flow of -672.93 million.
| Operating Cash Flow | -275.57M |
| Capital Expenditures | -397.37M |
| Depreciation & Amortization | 1.48B |
| Net Borrowing | -1.82M |
| Free Cash Flow | -672.93M |
| FCF Per Share | -49.79 |
Margins
Gross margin is 32.40%, with operating and profit margins of 9.39% and 15.07%.
| Gross Margin | 32.40% |
| Operating Margin | 9.39% |
| Pretax Margin | 15.09% |
| Profit Margin | 15.07% |
| EBITDA Margin | 20.19% |
| EBIT Margin | 9.39% |
| FCF Margin | n/a |
Dividends & Yields
PanGen Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.18% |
| Shareholder Yield | -14.18% |
| Earnings Yield | 3.04% |
| FCF Yield | -0.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PanGen Biotech has an Altman Z-Score of 18.49 and a Piotroski F-Score of 2.
| Altman Z-Score | 18.49 |
| Piotroski F-Score | 2 |